OR-POWIN
7.5.2024 15:01:37 CEST | Business Wire | Press release
Global energy storage platform provider Powin LLC (Powin) today announced its new multi-cell-based hardware platform, the Powin Pod (Pod). Designed for utility-scale projects, Pod takes Powin’s battery energy storage system (BESS) technology to the next level, setting a new standard for energy storage solutions with higher energy density, top-tier safety, reliability and enhanced cost savings. The Pod platform complements Powin's Centipede product line, offering a comprehensive suite of solutions to meet diverse customer requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507995695/en/
Powin's new multi-cell-based hardware platform, the Powin Pod. (Photo: Business Wire)
"We consistently challenge ourselves to improve our products and services to ensure we are continuously delivering nothing short of excellence to both new and existing customers," said Jeff Waters, CEO of Powin. "This next-generation product advancement demonstrates our commitment to bringing the safest and highest quality energy storage solutions to the market, advancing the entire industry as a result."
The new Pod platform is part of a fully integrated Powin energy storage solution that includes an end-to-end offering—spanning StackOS software, system design, delivery, commissioning and long-term service—that will enable Powin to meet growing customer needs with an improved, reliable and energy-dense storage platform. Powin’s proprietary Battery Management System and Energy Management controls comply with robust localized cybersecurity standards and regulations, ensuring superior protection for data privacy and intellectual property, guaranteeing security of customers’ data, operations and investment at all times. Customers who select Pod will benefit from Powin's full authorization to perform long-term services at their site, as well as comprehensive system training from the company. Within a fully integrated solution, Powin delivers safety, availability, insight and flexibility, providing lower risk, enhanced performance and improved revenue generation.
The Powin Pod platform offers benefits such as:
- Higher-density energy storage: Upgraded cell capacity, utilization of cell-to-pack technology and optimized internal space maximizes energy density and results in significant land savings for projects. Powin Pod delivers a 50% increase in energy density from the Powin Centipede platform. This solution and density improvement is available at 2-hour or greater system applications.
- Top-tier safety and reliability: Liquid cooling provides more stable internal battery system temperatures, ensuring enhanced system safety and longevity. Powin complies with the latest and most stringent fire prevention standards such as UL9540A, NFPA 68 and NFPA 69, while having optional class-leading fire suppression at module and container level.
- Enhanced cost savings: Powin Pod’s compact size reduces the amount of land required for installation, and Powin’s faster and lower cost shipping and on-time delivery combined with simplified installation and commissioning processes allow for lower CAPEX and greater customer savings.
With a proven track record of over 17 GWh deployed and under construction worldwide and over six million battery cells monitored, Powin is a trusted and established US-based integrator. Powin provides world-class logistics for on-time delivery, 20-year performance guarantee and long-term service structures and relies on a 24/7 Remote Operations Center and over 500 field service technicians and Authorized Service Providers to ensure optimal system performance.
Powin Pod is now available to order in markets globally and delivery is expected to begin in mid-2025. Starting in 2026, Powin Pod will be manufactured in the US complying with US Domestic Content requirements. To learn more about Powin’s latest product advancements, please visit https://powin.com/powin-pod/ or visit the Powin team at CLEANPOWER 2024 at booth #2645.
About Powin, LLC (Powin)
At Powin, we are advancing the next frontier of energy and changing the way we power our daily lives by ensuring access to clean, resilient, and affordable power. As a global energy storage platform provider, we offer fully integrated battery solutions, software, and services to optimize grid performance and enable the transition to cleaner energy sources. To learn more, please visit www.powin.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507995695/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom